Arrowhead Pharmaceuticals
Presence
Arrowhead Pharmaceuticals is one of the...
Arrowhead Pharmaceuticals is a company listed under the stock ticker ARWR (US).
Executives
View the org chart displaying its 29 main executives
Most searched biographies at Arrowhead Pharmaceuticals
- Christopher Anzalone, President, Chief Executive Officer, Director
- Douglass Given, Chairman of the Board
- Mauro Ferrari, Director
Popular executive movements at Arrowhead Pharmaceuticals
- Javier San Martin, Chief Medical Officer, will leave the company on Feb. 1, 2024 (posted on January 23 2024).
Create your alert
to follow the executive moves at Arrowhead Pharmaceuticals.
Biotechnology
Arrowhead Pharmaceuticals has 2,275 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
- Bruker has announced the acquisition of NanoString Technologies (posted on April 18 2024).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (posted on April 16 2024).
Popular contacts in Biotechnology
News
Press releases by Arrowhead Pharmaceuticals
- Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo - Arrowhead Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Arrowhead Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data - Arrowhead Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy - Arrowhead Pharmaceuticals, Inc.
- GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen | Arrowhead Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results | Arrowhead Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Third Quarter Results | Arrowhead Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy | Arrowhead Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1 | Arrowhead Pharmaceuticals Inc.
- Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease | Arrowhead Pharmaceuticals Inc.
- View more press releases Close
Social media about Arrowhead Pharmaceuticals
- Arrowhead Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Arrowhead Pharmaceuticals on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Christopher Anzalone 
Call Arrowhead Pharmaceuticals at +1 626...
